


# **Supplementary Material**

## **Zinc-finger protein p52-ZER6 accelerates colorectal cancer cell proliferation and tumour progression through promoting p53 ubiquitination**

Can Huang, Shourong Wu, Wenfang Li, Arin Herkilini, Makoto Miyagishi, Hezhao Zhao,  
Vivi Kasim\*


\*Email: [vivikasim@cqu.edu.cn](mailto:vivikasim@cqu.edu.cn) (V.K.)

## Supplementary Figure S1




**Fig. S1. The efficacy of shRNA expression vectors targeting ZER6.** ZER6 mRNA expression level in HCT116 cells transfected with shRNA expression vectors targeting different sites of ZER6, as determined using quantitative RT-PCR (qPCR). Cells transfected with control vector (shCon) were used as control.  $\beta$ -Actin was used for qPCR normalization. Data were shown as mean  $\pm$  SEM of three independent experiments. \*\* $P < 0.01$  (ANOVA).

## Supplementary Figure S2




**Fig. S2. p52-ZER6 regulates p21 transcriptional activity.** **a** Schematic diagram of the nucleotide sequences of ZER6 isoforms mRNA. Homologous sequences were shown in same colours. **b** Schematic diagram of the shRNA target sites targeting the whole ZER6, and shRNA target sites specifically targeting p52-ZER6 and p71-ZER6. **c** Schematic diagram of the location of qPCR primer pairs for detection of the whole ZER6, and for specific detections of p52-ZER6 and p71-ZER6. **d** p71-ZER6 mRNA expression level in p52-ZER6-silenced HCT116 cells (left); and p52-ZER6 mRNA expression level in p71-ZER6-silenced HCT116 cells (right), as determined using qPCR. **e** p71-ZER6 protein expression level in p52-ZER6-silenced HCT116 cells (left); and p52-ZER6 protein expression level in p71-ZER6-silenced HCT116 cells (right), as determined using western blotting. **f** Activity of p21 reporter in p52-ZER6- (left) and p71-ZER6-silenced HCT116 cells (right), as determined using dual luciferase assay. Cells transfected with control vector (shCon) were used as control. β-Actin was used for qPCR normalization. Data were shown as mean ± SEM of three independent experiments. \*\* $P < 0.01$ ; NS: not significant (ANOVA).

## Supplementary Figure S3




**Fig. S3. p52-ZER6 expression is negatively correlated with p21.** **a** Correlation analysis of ZER6 and p21 in hepatocellular carcinoma specimens (GEO data set: GSE25097,  $n = 184$ ). **b** p52-ZER6 and p21 mRNA expression levels in *p52-ZER6*-silenced HCT116 stable cell lines HCT116/shp52-1 and HCT116/shp52-2, as determined using qPCR. **c** p52-ZER6 and p21 protein expression levels in *p52-ZER6*-silenced HCT116 stable cell lines HCT116/shp52-1 and HCT116/shp52-2, as analysed using western blotting. The stable cell lines were obtained using two shRNA expression vectors targeting different sites of p52-ZER6 (shp52-1 and shp52-2), and were established from single clones. Stable cell line obtained using control vector (shCon) was used as control.  $\beta$ -Actin was used for qPCR normalization and as western blotting loading control. Quantitative data were shown as mean  $\pm$  SEM of three independent experiments. \*\* $P < 0.01$  (ANOVA).

## Supplementary Figure S4




**Fig. S4. *p52-ZER6* overexpression enhances tumor cells proliferation.** **a** Total cell number of HCT116 cells overexpressing *p52-ZER6* at the indicated time points. **b** Number of proliferative HCT116 cells overexpressing *p52-ZER6*, as determined by the EdU incorporation assay. Representative images (left) and the percentage of EdU-positive cells to DAPI positive cells (right) were shown. Quantitative data were shown as mean  $\pm$  SEM of three independent experiments. \* $P < 0.05$ ; \*\* $P < 0.01$  (ANOVA); pcp52: *p52-ZER6* overexpression vector.

## Supplementary Figure S5




**Fig. S5. Establishment of the *p52-ZER6* and *p21* double-knockdown system.** **a** *p52-ZER6* and *p21* mRNA expression levels in HCT116 cells transfected with both shRNAs targeting *p52-ZER6* and *p21*, as determined using qPCR. **b** *p52-ZER6* and *p21* protein expression levels in HCT116 cells transfected with both shRNAs targeting *p52-ZER6* and *p21*, as analysed using western blotting. Cells transfected with control vector (shCon) were used as controls.  $\beta$ -Actin was used for qPCR normalization and as western blotting loading control. Quantitative data were shown as mean  $\pm$  SEM of three independent experiments.  $**P < 0.01$  (ANOVA).

## Supplementary Figure S6



**Fig. S6. p52-ZER6 suppresses p21 expression level through p53 post-translational regulation.** **a** p52-ZER6 mRNA expression level in HCT116<sup>p53null</sup> cells transfected with shRNA vectors targeting *p52-ZER6*, as determined using qPCR. **b** The protein expression levels of cyclin D1 and cyclin E in HCT116<sup>p53null</sup> cells transfected with shRNA vectors targeting *p52-ZER6*, as determined using western blotting. **c** p53 protein expression level in *p52-ZER6* silenced HCT116 cells treated with transcriptional inhibitor actinomycin D, or *de novo* protein synthesis inhibitor cycloheximide (30 μg/ml), as analysed using western blotting. Cells treated with DMSO were used as control. **d** p53 and p21 protein expression levels in *p52-ZER6*-silenced human HepG2 hepatocellular carcinoma cell line (left) and human U2OS sarcoma cell line (right), as analysed using western blotting. β-Actin was used for qPCR normalization and as western blotting loading control. Cells transfected with shCon were used as control. Quantitative data were shown as mean ± SEM of three independent experiments. \*\**P* < 0.01 (ANOVA).


## Supplementary Figure S7



**Fig. S7. MDM2 is necessary for p52-ZER6 regulation on p53 protein accumulation.** **a–b** Physical interactions between p52-ZER6 and p53 (a) or MDM2 (b) in HCT116 cells overexpressing *p52-ZER6* and *p53* or *MDM2*, as determined by anti-p53 or anti-MDM2 immunoblotting of cell lysate immunoprecipitated with anti-FLAG antibody, and *vice versa*. **c** Protein expression level of MDM2 in *MDM2*-silenced HCT116 cells, as determined using western blotting. **d** p53 and p21 protein expression levels in *MDM2*-silenced HCT116 cells overexpressing *p52-ZER6*, as analysed using western blotting. **e** MDM2 protein expression level in *p52-ZER6*-silenced HCT116 cells, as determined using western blotting. β-Actin was used as western blotting loading control.




## Supplementary Figure S8




**Fig. S8. The role of tKRAB domain in p52-ZER6-mediated tumour cells proliferation. a** Schematic diagram of the FLAG-conjugated N terminal and C terminal fragments of p52-ZER6 (FLAG-p52-N and FLAG-p52-C, respectively), and NLS-fused N terminal fragment of p52-ZER6 (FLAG-p52-N-NLS). **b** Schematic diagram of FLAG-conjugated p52-ZER6 fragment lacking tKRAB domain (FLAG-p52<sup>tKdel</sup>) and NLS-fused N terminal fragment of p52-ZER6 lacking tKRAB domain (FLAG-p52-N-NLS<sup>tKdel</sup>). **c** Total cell number of HCT116 cells overexpressing *FLAG-p52<sup>tKdel</sup>* at the indicated time points. **d** Number of proliferative HCT116 cells overexpressing *p52<sup>tKdel</sup>*, as determined by the EdU incorporation assay. Representative images (left) and the percentage of EdU-positive cells to DAPI positive cells (right) were shown. Quantitative data were shown as mean  $\pm$  SEM of three independent experiments. \*\* $P < 0.01$ ; NS: not significant;  $P$  values were analysed using ANOVA.

## Supplementary Figure S9



**Fig. S9. Schematic diagram of various p52-ZER6 and p71-ZER6 fragments.** Schematic diagram of various fragments with intermediate length and sequences between p52-ZER6 and p71-ZER6 conjugated with FLAG: FLAG-p52-ZER6, FLAG-KRAB-p52-ZER6 (FLAG-p52<sup>K</sup>), FLAG-HUB-1/KRAB-p52-ZER6 (FLAG-p52<sup>KH</sup>) and FLAG-p71-ZER6. F: FLAG.

## Supplementary Figure S10



**Fig. S10. p71-ZER6 enhances cell proliferation and colony formation potentials.** **a** Total cell number of HCT116 cells overexpressing *p71-ZER6* at the indicated time points. **b** Number of proliferative HCT116 cells overexpressing *p71-ZER6*, as determined by the EdU incorporation assay. Representative images (left) and the percentage of EdU-positive cells to DAPI positive cells (right) were shown. **c** Colony formation potential of HCT116 cells overexpressing *p71-ZER6*. Representative images (left) and quantification results (right) were shown. Cells transfected with pcCon were used as controls. \*\* $P < 0.01$  (ANOVA).

**Supplementary Table S1.**

Primer pairs used for gene quantification by quantitative PCR.

<b>Gene</b>	<b>RefSeq No.</b>	<b>Forward (5'-3')</b>	<b>Reverse (5'-3')</b>
<i>p21</i>	NM_000389.4	TCACTGTCTTGTACCCTTGTGC	GGCGTTTGGAGTGGTAGAAA
<i>ZER6</i>	Common for NM_170686.2 & NM_020781.3	CCAGAAGGGGAACATAATACAGA	CTGATGTTGAAATACCAGGCTCT
<i>p52-ZER6</i>	Specific for NM_020781.3	TGCGGTCGAAGACGAGAT	TCCTGCTCTCTCCATGTTCA
<i>p71-ZER6</i>	Specific for NM_170686.2	GTCCGTGCGGGGAAGGCA	CCATGGCCCTGCGCTGTCT
<i>β-Actin</i>	NM_001101.3	CGAGCGCGGCTACAGCTT	TCCTTAATGTCACGCACGATTT

## Supplementary Table S2.

Antibodies used for western blotting, immunohistochemistry, immunofluorescence and immunoprecipitation.

Antibody	Maker	Product number	Experiment	Dilution
anti-β-Actin	Proteintech	60008-1- Ig	Western Blotting	1/50000
anti-ZNF398 (anti-ZER6)	GeneTex	GTX107221	Western Blotting	1/1000
anti-p21	Proteintech	10355-1-AP	Western Blotting Immunohistochemistry	1/1000 1/50
anti-Cyclin D1	Santa Cruz Biotechnology	sc-8396	Western Blotting	1/500
anti-Cyclin E	Santa Cruz Biotechnology	sc-481	Western Blotting	1/300
anti-p53	Proteintech	10442-1-AP	Western Blotting Immunoprecipitation Immunohistochemistry Immunofluorescence	1/1000 5 µg/ml cell lysate 1/50 1/100
anti-MDM2	Santa Cruz Biotechnology	sc-965	Western Blotting Immunoprecipitation	1/100 5 µg/ml cell lysate
anti-FLAG	Sigma-Aldrich	F1804	Western Blotting	1/1000
anti-FLAG	Proteintech	66008-2-Ig	Immunoprecipitation Immunofluorescence	5 µg/ml cell lysate 1/100
anti-Ubiquitin	Proteintech	10201-2-AP	Ubiquitination assay	1/1000
Goat Anti-Rabbit IgG	ZSGB-BIO	ZB2301	Western Blotting	1/10000
Goat Anti-Mouse IgG	ZSGB-BIO	ZB2305	Western Blotting	1/10000
Alexa Fluor 488 Donkey Anti-rabbit IgG	Invitrogen	A21206	Immunofluorescence	1/500
Alexa Fluor 568 Goat Anti-mouse IgG	Invitrogen	A11004	Immunofluorescence	1/100
Goat Anti-Mouse/Rabbit Immunoglobulins/HRP	DAKO	K5007	Immunohistochemistry	not diluted
Mouse Anti-Rabbit IgG Light Chain	Abbkine	A25022	Western Blotting	1/10000
Goat Anti-Mouse IgG Light Chain	Abbkine	A25012	Western Blotting	1/10000